FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington.	D.C. 20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPI	ROVAL
OMB Number:	3235-0287
Estimated average bu	ırden
hours nor reenence:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Perfetti Riccardo</u>						2. Issuer Name and Ticker or Trading Symbol Applied Therapeutics Inc. [ APLT ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify				
	LIED THE	rirst) RAPEUTICS, II E, SUITE 1400	(Middle) NC.		3. Date 08/02/		t Transac	tion (Month/Da	ay/Year)	_ ^	below) below)  Chief Medical Officer						
(Street) NEW Y	ORK N	Y	10017	-	4. If Amendment, Date of Original Filed (Month/Day/Year)							S. Individual or Joint/Group Filing (Check Applicable Lin  X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(City) (State) (Zip)																	
1. Title of	Security (Inst		2	2. Transac							(A) or	or 5. Amount of 6. Ownersh				. Nature of	
• • • •			Date Month/Day/Year)		Execution Date, if any (Month/Day/Year)		Transaction Code (Instr. 8)	Amount (A) or		3, 4 and 5)	Beneficially (D) or Owned Following (I) (Instance Instance Instanc		Form: (D) or I (I) (Inst	ndirect E tr. 4) C	ndirect eneficial wnership nstr. 4)		
			Table II - D					ired, Dispo	sed of, c		cially Ov	(Instr. 3 and					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (	saction be (Instr. Calls, Warrants,   5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		options, convertible securitie  6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and At of Securities Underlying Derivative Securities Securities Securities Securities Securities Securities Securities Sec			I Amount es I Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
	Journey			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Report Transa (Instr.		ĭ	(-) (-110411)		
Employee Stock Option (Right to Buy)	\$2.02	08/02/2022		D <sup>(1)</sup>			50,000	(2)	04/13/2032	Common Stock	50,000	(1)	0		D		
Employee Stock Option (Right to Buy)	\$1.05	08/02/2022		D <sup>(1)</sup>		50,000		(2)	04/13/2032	Common Stock	50,000	(1)	50,00	00	D		
Employee Stock Option (Right to Buy)	\$4.17	08/02/2022		D <sup>(1)</sup>			32,100	(3)	01/07/2032	Common Stock	32,100	(1)	0		D		
Employee Stock Option (Right to Buy)	\$1.05	08/02/2022		D <sup>(1)</sup>		32,100		(3)	01/07/2032	Common Stock	32,100	(1)	32,10	00	D		
Employee Stock Option (Right to Buy)	\$9.44	08/02/2022		D <sup>(1)</sup>			32,100	(4)	12/14/2031	Common Stock	32,100	(1)	0		D		
Employee Stock Option Right to Buy)	\$1.05	08/02/2022		D <sup>(1)</sup>		32,100		(4)	12/14/2031	Common Stock	32,100	(1)	32,100		D		
Employee Stock Option Right to Buy)	\$23.15	08/02/2022		D <sup>(1)</sup>			36,495	(5)	12/10/2030	Common Stock	36,495	(1)	0		D		
Employee Stock Option (Right to Buy)	\$1.05	08/02/2022		D <sup>(1)</sup>		36,495		(5)	12/10/2030	Common Stock	36,495	(1)	36,4	95	D		
Employee Stock Option (Right to Buy)	\$22.2	08/02/2022		D <sup>(1)</sup>			51,666	(6)	12/16/2029	Common Stock	51,666	(1)	0		D		
Employee Stock Option Right to Buy)	\$1.05	08/02/2022		D <sup>(1)</sup>		51,666		(6)	12/16/2029	Common Stock	51,666	(1)	51,60	66	D		

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Employee Stock Option (Right to Buy)	\$10	08/02/2022		D <sup>(1)</sup>			134,997	(7)	05/12/2029	Common Stock	134,997	(1)	0	D	
Employee Stock Option (Right to Buy)	\$1.05	08/02/2022		D <sup>(1)</sup>		134,997		(7)	05/12/2029	Common Stock	134,997	(1)	134,997	D	

## **Explanation of Responses:**

- 1. The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.
- 2. Reflects an initial grant of 50,000 Options granted on April 13, 2022 that vests as follows: One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on April 13, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.
- 3. Reflects an initial grant of 32,100 Options granted on January 7, 2022 that vests as follows: One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on January 7, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.
- 4. Reflects an initial grant of 32,100 Options granted on December 14, 2021 that vests as follows: One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on December 14, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.
- 5. Reflects an initial grant of 36,495 Options granted on December 10, 2020 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on December 10, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.
- 6. Reflects an initial grant of 51,666 Options granted on December 16, 2019 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on December 16, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.
- 7. Reflects an initial grant of 170,522 Options granted on May 13, 2019 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on May 13, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

## Domarke

/s/ Shoshana Shendelman, as attorney-in-fact

08/04/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.